GVHD Clinical Trial
Official title:
Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Verified date | February 2023 |
Source | Icahn School of Medicine at Mount Sinai |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Graft-versus-host disease (GVHD) is treated with high doses of systemic steroids which can lead to serious complications. A new blood test can identify patients whose GVHD is most likely to respond to well to treatment (low risk GVHD). This study will test whether patients with low risk GVHD can be successfully treated without steroids. Patients who participate with this study will be treated with itacitinib instead of steroids. Itacitinib is an experimental drug with an excellent safety record and appears to have activity as a GVHD treatment.
Status | Completed |
Enrollment | 70 |
Est. completion date | May 11, 2022 |
Est. primary completion date | May 7, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 75 Years |
Eligibility | Inclusion Criteria: - Newly diagnosed GVHD that meets criteria for Minnesota standard risk - Ann Arbor 1 GVHD by biomarkers - GVHD not previously treated systemically (topical therapies and non-absorbed steroids are allowed) - Any donor type, HLA-match, conditioning regimen is acceptable - Age 12 - 75 years (children <18 years must also weigh 50 kg or more) - Patients must be engrafted post-transplant (ANC >500/µL and platelet count >20,000). Use of growth factor supplementation to maintain neutrophil count is allowed. - Direct bilirubin must be <2 mg/dL unless the elevation is known to be due to Gilbert syndrome within 3 days prior to enrollment. - ALT/SGPT and AST/SGOT must be <5x the upper limit of the normal range within 3 days prior to enrollment. - Signed and dated written informed consent obtained from patient or legal representative. Exclusion Criteria: - Patients currently being treated with any JAK inhibitor including ruxolitinib - Relapsed, progressing, or persistent malignancy requiring withdrawal of systemic immune suppression - Patients with uncontrolled infection (i.e., progressive symptoms related to infection despite treatment or persistently positive microbiological cultures despite treatment or any other evidence of severe sepsis) - Severe organ dysfunction including requirement for dialysis, mechanical ventilation or oxygen supplementation exceeding 40% FiO2 within 7 days of enrollment. - Creatinine clearance or estimated glomerular filtration rate <30 ml/min as calculated by institutional practice (e.g., Cockcroft-Gault equation, CKD-EPI equation, etc) - A clinical presentation resembling de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment - Patients receiving corticosteroids >10 mg/day prednisone (or other steroid equivalent) for any indication within 7 days before the onset of acute GVHD except for adrenal insufficiency or premedication for transfusions/IV meds - Patients who are pregnant - Patients receiving investigational agents within 30 days of enrollment. However, the Principal Investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of itacitinib - History of allergic reaction to itacitinib or any JAK inhibitor |
Country | Name | City | State |
---|---|---|---|
United States | Children's Healthcare of Atlanta | Atlanta | Georgia |
United States | Emory University | Atlanta | Georgia |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Ohio State University | Columbus | Ohio |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | University of Kansas Cancer Center | Fairway | Kansas |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | Children's Hospital of Los Angeles | Los Angeles | California |
United States | Vanderbilt University | Nashville | Tennessee |
United States | The Mount Sinai Hospital | New York | New York |
United States | Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | University of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Fred Hutchinson Cancer Research Center | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
John Levine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Patients Who Achieve CR or PR by Day 28 of Treatment | Number of patients who achieve CR or PR by day 28 of treatment with itacitinib without the addition of any other systemic GVHD treatment including steroids.
Complete Response (CR): All evaluable organs (skin, liver, GI tract) stage 0. For a response to be scored as CR on day 28, the patient must be in CR on that day and have had no intervening additional GVHD therapy. Partial Response (PR): An improvement in one or more organ involved with GVHD symptoms without worsening in others. For a response to be scored as PR on day 28, the patient must be in PR on that day and have had no intervening additional GVHD therapy. |
Day 28 | |
Primary | Number of Participants Who Developed Steroid Refractory GVHD | Number of participants who developed steroid refractory GVHD within 28 days of starting steroids. Steroid-refractory GVHD (defined as GVHD that worsens (increase by one or more grade) after 3 days, or fails to respond to treatment within 7 days (for GVHD grade III) or 14 days (for GVHD grade II) or 2nd line therapy beyond systemic steroid treatment is begun within 28 days of starting steroids. | Day 28 | |
Secondary | Number of Participants With Serious Infectious | Number of participants who developed serious infections by day 90. Serious infectious complications is defined as any viral and bacterial infections requiring treatment and proven fungal infections. | Day 90 | |
Secondary | Number of Participants Alive at 6 Months and 1 Year | Number of overall survival (OS), defined as the duration from the date of diagnosis to death or last follow-up, with no restriction on the cause of death. | 6 months and 1 year | |
Secondary | Number of Participants With Non-relapse Mortality (NRM) | Number of participants with non-relapse mortality (NRM) at 6 months and 1 year | 6 months and 1 year | |
Secondary | Number of Participants Who Relapsed | Number of participants who relapsed by 6 months and by 1 year | 6 months and 1 year | |
Secondary | Number of Participants Who Developed Chronic GVHD | Number of participants who developed chronic GVHD requiring systemic treatment at 1 year | 1 year | |
Secondary | Cumulative Steroid Dose | Cumulative steroid dose (over 4 weeks) in patients who receive steroids as second line therapy | Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02942173 -
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
|
Phase 2/Phase 3 | |
Completed |
NCT02066051 -
IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD
|
N/A | |
Terminated |
NCT01940796 -
Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
|
Phase 1 | |
Not yet recruiting |
NCT05544448 -
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
|
N/A | |
Completed |
NCT01295710 -
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
|
Phase 3 | |
Not yet recruiting |
NCT06000982 -
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis
|
Phase 3 | |
Not yet recruiting |
NCT06075225 -
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
|
Phase 2 | |
Active, not recruiting |
NCT03680092 -
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT06083129 -
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor
|
Phase 3 | |
Not yet recruiting |
NCT05094765 -
Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD
|
Early Phase 1 | |
Active, not recruiting |
NCT05415410 -
Proof-of-concept Trial of Apraglutide in GVHD
|
Phase 2 | |
Completed |
NCT02441075 -
70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014
|
N/A | |
Completed |
NCT02588339 -
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
|
Phase 2 | |
Not yet recruiting |
NCT06334367 -
Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT
|
Phase 2 | |
Completed |
NCT02891603 -
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
|
Phase 1/Phase 2 | |
Completed |
NCT02712762 -
Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients
|
||
Completed |
NCT03945591 -
High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Not yet recruiting |
NCT06411184 -
Safety and Efficacy of Treg Cell in the Treatment of GVHD
|
Phase 1/Phase 2 | |
Terminated |
NCT02338232 -
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02156479 -
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients
|